EVIDENTIARY CLINICAL SUPPORT:
Parker LN, Gray DR, Lai MK, et al. Treatment of gynecomastia with
tamoxifen: a double-blind crossover study. Metabolism 1986; 35:705–708.
Jones DJ, Holt SD, Surtees P, et al. A comparison of danazol and placebo in the treatment of adult idiopathic gynecomastia: results of a prospective study in 55 patients. Ann R Coll Surg Engl 1990; 72:296–298.
Ting AC, Chow LW, Leung YF. Comparison of tamoxifen with danazol in the management of idiopathic gynecomastia. Am Surg 2000; 66:38–40.
Bishop JF; Smith JG; Jeal PN; Murray R; Drummond RM; Pitt P; Olver IN; Bhowal AK. The effect of danazol on tumour control and weight loss in patients on tamoxifen therapy for advanced breast cancer: a randomised double-blind placebo controlled trial. Eur J Cancer 1993;29A(6):814-8.
Powles TJ, Ashley S, Ford HT, Gazet JC, Nash AG, Neville AM, Coombes RC. Treatment of disseminated breast cancer with tamoxifen, aminoglutethimide, hydrocortisone, and danazol, used in combination or sequentially, Lancet, 1984 Jun 23;1(8391):1369-73.
Jan G. M. Klijn, et. al, Combined Treatment With Buserelin and Tamoxifen in Premenopausal Metastatic Breast Cancer: a Randomized Study, Journal of the National Cancer Institute, Vol. 92, No. 11, ***-911, June 7, 2000
Note: As evidenced within the studies above, the effects of three or even two anti-gyno drugs are synergistically enhanced when administered concurrently or sequentially, rather than merely singularly.